Latest Conference Content

Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial.

Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.

Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.

The Association of Community Cancer Centers (ACCC) 49th Annual Meeting and Cancer Center Business Summit will feature presentations and interactive workshops centered on the latest in technology, care delivery, and payment issues in oncology.

The findings of the ACCESS study show the complex challenge of improving medication adherence among the most fragile members of society.

Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed that the therapy caused a sustained, dose-dependent reduction in plasma aldosterone by more than 70% without reducing cortisol.

Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia. 

The 72nd American College of Cardiology Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC), runs from Saturday to Monday in New Orleans, Louisiana.

Braden Manns, MD, MSc, a nephrologist and health economics researcher at the University of Calgary in Canada, will present the results of a randomized trial evaluating the impact of removing co-payments for drugs that treat chronic conditions on cardiovascular outcomes during the American College of Cardiology Scientific Sessions in New Orleans, Louisiana, on Sunday, March 5.

Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.

At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.

A panel of experts discussed the explosion of information and advances in cancer genomics and the accompanying challenges of understanding the data and taking action.

Guideline-directed cancer care—with help from a clinical support tool—can close disparities while reducing costs more efficiently than other means, such as prior authorization.

While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, according to an analysis of real-world data.

Two studies looking at a higher dose of aflibercept found that an 8-mg dose can be maintained at longer dosing intervals with similar benefits and no additional safety signals compared with the 2-mg dose.

Much of the evidence that has been used to base current standard of care for diabetic eye diseases stems from studies performed by the DRCR Retina Network over the years.

The BUTTERFLEYE trial sought to determine if aflibercept, an anti–vascular endothelial growth factor (anti-VEGF) therapy, was equivalent to laser photocoagulation, the gold standard to treat retinopathy of prematurity (ROP) in preterm babies.

Patients with wet age-related macular degeneration (AMD) who are responsive to anti–vascular endothelial growth factor (anti-VEGF) therapy experienced visual gains with no additional injections in the 6 months after treatment with the gene therapy.

Home optical coherence tomography (OCT) has shown there is a wide degree of heterogeneity in fluid dynamics and treatment response that may not be clear during regular office visits and scans. Presenters reviewed the latest data in home OCT to manage wet age-related macular degeneration (AMD).

A review of data on 2 mitochondrial membrane stabilizers—risuteganib and elamipretide—has highlighted the potential to not just slow disease progression but actually reverse vision loss in patients with intermediate dry age-related macular degeneration (AMD).

For patients with geographic atrophy (GA) taking pegcetacoplan, the drug’s effect to slow disease progression increases over time as patients take the drug, said Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

The Angiogenesis, Exudation, and Degeneration 2023 meeting will be held virtually with a program focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.

With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

Although allogenic stem cell transplant is increasingly used to treat multiple myeloma (MM) and other hematological conditions, there have been mixed efficacy results in the context of MM.

Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.

The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.

New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.

Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.